Gastric Cancer--the Recognition of a Chemosensitive Tumour

Overview

Journal Br J Cancer

Specialty Oncology

Date 1988 Dec 1

PMID 3066394

Citations 2

Authors

D Cunningham

Affiliations

Soon will be listed here.

Citing Articles

Downregulation of PSCA promotes gastric cancer proliferation and is related to poor prognosis.

Xu L, Qiu H, Yuan S, Chen Y, Zhou Z, Chen Y J Cancer. 2020; 11(9):2708-2715.

PMID: 32201541 PMC: 7066023. DOI: 10.7150/jca.33575.

Histopathological assessment of multidrug resistance in gastric cancer: expression of P-glycoprotein, multidrug resistance-associated protein, and lung-resistance protein.

Alexander D, Yamamoto T, Kato S, Kasai S Surg Today. 1999; 29(5):401-6.

PMID: 10333409 DOI: 10.1007/BF02483030.

References

LONGMIRE Jr W, KUZMA J, DIXON W . The use of triethylenethiophosphoramide as an adjuvant to the surgical treatment of gastric carcinoma. Ann Surg. 1968; 167(3):293-312. PMC: 1387057. DOI: 10.1097/00000658-196803000-00001. View

. Controlled trial of adjuvant chemotherapy following curative resection for gastric cancer. The Gastrointestinal Tumor Study Group. Cancer. 1982; 49(6):1116-22. DOI: 10.1002/1097-0142(19820315)49:6<1116::aid-cncr2820490609>3.0.co;2-u. View

Gunderson L, SOSIN H . Adenocarcinoma of the stomach: areas of failure in a re-operation series (second or symptomatic look) clinicopathologic correlation and implications for adjuvant therapy. Int J Radiat Oncol Biol Phys. 1982; 8(1):1-11. DOI: 10.1016/0360-3016(82)90377-7. View

Bruckner H, Lokich J, Stablein D . Studies of Baker's antifol, methotrexate, and razoxane in advanced gastric cancer: A Gastrointestinal Tumor Study Group Report. Cancer Treat Rep. 1982; 66(9):1713-7. View

Lavin P, Bruckner H, Plaxe S . Studies in prognostic factors relating to chemotherapy for advanced gastric cancer. Cancer. 1982; 50(10):2016-23. DOI: 10.1002/1097-0142(19821115)50:10<2016::aid-cncr2820501007>3.0.co;2-2. View

Fraschini P, Beretta G, Arnoldi E, Tedeschi L, Labianca R, LUPORINI G . Confirmed activity of FAM polychemotherapy in advanced gastric carcinoma. Tumori. 1983; 69(1):59-64. DOI: 10.1177/030089168306900110. View

Beer M, COCCONI G, Ceci G, Varini M, Cavalli F . A phase II study of cisplatin in advanced gastric cancer. Eur J Cancer Clin Oncol. 1983; 19(6):717-20. DOI: 10.1016/0277-5379(83)90003-2. View

FIELDING J, Fagg S, Jones B, Ellis D, Hockey M, Minawa A . An interim report of a prospective, randomized, controlled study of adjuvant chemotherapy in operable gastric cancer: British Stomach Cancer Group. World J Surg. 1983; 7(3):390-9. DOI: 10.1007/BF01658089. View

Higgins G, Amadeo J, Smith D, HUMPHREY E, KEEHN R . Efficacy of prolonged intermittent therapy with combined 5-FU and methyl-CCNU following resection for gastric carcinoma. A Veterans Administration Surgical Oncology, Group report. Cancer. 1983; 52(6):1105-12. DOI: 10.1002/1097-0142(19830915)52:6<1105::aid-cncr2820520629>3.0.co;2-z. View

10.

Boice Jr J, Greene M, Killen Jr J, Ellenberg S, KEEHN R, McFadden E . Leukemia and preleukemia after adjuvant treatment of gastrointestinal cancer with semustine (methyl-CCNU). N Engl J Med. 1983; 309(18):1079-84. DOI: 10.1056/NEJM198311033091802. View

11.

Leichman L, McDonald B, Dindogru A, Samson M, VAITKEVICIUS V . Cisplatin. An active drug in the treatment of disseminated gastric cancer. Cancer. 1984; 53(1):18-22. DOI: 10.1002/1097-0142(19840101)53:1<18::aid-cncr2820530105>3.0.co;2-j. View

12.

Cunningham D, Soukop M, McArdle C, Carter D, Smyth J, Allan S . Advanced gastric cancer: experience in Scotland using 5-fluorouracil, adriamycin and mitomycin-C. Br J Surg. 1984; 71(9):673-6. DOI: 10.1002/bjs.1800710909. View

13.

Cullinan S, MOERTEL C, Fleming T, Rubin J, Krook J, Everson L . A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin. JAMA. 1985; 253(14):2061-7. View

14.

Engstrom P, Lavin P, Douglass Jr H, BRUNNER K . Postoperative adjuvant 5-fluorouracil plus methyl-CCNU therapy for gastric cancer patients. Eastern Cooperative Oncology Group study (EST 3275). Cancer. 1985; 55(9):1868-73. DOI: 10.1002/1097-0142(19850501)55:9<1868::aid-cncr2820550904>3.0.co;2-b. View

15.

Cunningham D, Gilchrist N, Forrest G, Soukop M, McArdle C, Carter D . Chemotherapy in advanced gastric cancer. Cancer Treat Rep. 1985; 69(7-8):927-8. View

16.

Lacave A, Wils J, Diaz-Rubio E, Clavel M, Planting A, Bleiberg H . cis-Platinum as second-line chemotherapy in advanced gastric adenocarcinoma. A phase II study of the EORTC Gastrointestinal Tract Cancer Cooperative Group. Eur J Cancer Clin Oncol. 1985; 21(11):1321-4. DOI: 10.1016/0277-5379(85)90311-6. View

17.

Cersosimo R, Hong W . Epirubicin: a review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue. J Clin Oncol. 1986; 4(3):425-39. DOI: 10.1200/JCO.1986.4.3.425. View

18.

Cazap E, Gisselbrecht C, Smith F, ESTEVEZ R, Alvarez C, Lagarde C . Phase II trials of 5-FU, doxorubicin, and cisplatin in advanced, measurable adenocarcinoma of the lung and stomach. Cancer Treat Rep. 1986; 70(6):781-3. View

19.

LEVI J, Fox R, Tattersall M, Woods R, Thomson D, Gill G . Analysis of a prospectively randomized comparison of doxorubicin versus 5-fluorouracil, doxorubicin, and BCNU in advanced gastric cancer: implications for future studies. J Clin Oncol. 1986; 4(9):1348-55. DOI: 10.1200/JCO.1986.4.9.1348. View

20.

Allum W, Hallissey M, Dorrell A, Low J, FIELDING J . Programme for early detection of gastric cancer. Br Med J (Clin Res Ed). 1986; 293(6546):541. PMC: 1341315. DOI: 10.1136/bmj.293.6546.541. View